Released Aug 11, 2023, after the close
10-Q filed Aug 11, 2023, 42 days after period end · 0001140361-23-039283
Q2 2023 · 10-Q
Revenue—
Net Income-$4.51M-$4.51M N/M vs Q2 2022N/M vs Q1 2023
EPS Diluted-$0.85-$0.85 N/M vs Q2 2022N/M vs Q1 2023
Gross Profitderived$0—
Operating Income-$4,549,000N/M
Operating Cash Flowderived-$3,872,000N/M
Free Cash Flowderived-$3,872,000N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Revenue | — | — | — | $754.00K |
| Net Income | -$4.51M | -$3.40M | -$10.09M | -$2.03M |
| EPS Diluted | -$0.85 | -$1.16 | -$0.24 | -$0.12 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR